Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo shares rise as US Medicare price cuts come in largely as expected
08:22am, Wednesday, 26'th Nov 2025
Novo Nordisk shares rose 5% on Wednesday after analysts said that U.S. price cuts for the Danish drugmaker's semaglutide came in broadly as expected.
Wall Street Breakfast Podcast: HP Downsizes To Power Up
06:50am, Wednesday, 26'th Nov 2025
HP (HPQ) shares dropped 6% after issuing a weak forecast and announcing up to 6,000 job cuts despite beating quarterly earnings estimates. The Trump administration secured a 71% Medicare discount on O
Novo Nordisk Faces 71% Medicare Price Cuts on Ozempic and Wegovy
06:13am, Wednesday, 26'th Nov 2025
Novo Nordisk (NVO, Financials) will face steep reductions in Medicare pricing after U.S. regulators negotiated a 71% cut for Ozempic, Wegovy and Rybelsus. The C
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month
05:11am, Wednesday, 26'th Nov 2025
The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications.
Why Novo Nordisk Stock Keeps Getting Punished For Headlines That Don't Matter
02:29pm, Tuesday, 25'th Nov 2025
Novo Nordisk A/S (NYSE: NVO) shouldn't be trading like a meme stock — not when it's sitting on deep-value fundamentals, a GLP-1 fortress, and a pipeline pivot that could flip 2026 from bruised to br
Here's Why Novo Nordisk Stock Popped Today
01:37pm, Tuesday, 25'th Nov 2025
The company's highly promising drug, amycretin, reported impressive results in a trial for Type 2 diabetes. The news follows on for a disappointing, but hardly unexpected, result in a Phase 3 trial fo
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says
01:24pm, Tuesday, 25'th Nov 2025
Novo Nordisk A/S (NYSE: NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's
Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill
01:18pm, Tuesday, 25'th Nov 2025
Novo Nordisk A/S remains the market leader in obesity and diabetes treatments, despite a recent sharp stock drop and failed Alzheimer's trial. The real growth catalyst for NVO is the upcoming oral sem
Novo's Comeback Shot? Weight-Loss Drug Triggers Surprise Rally After Brutal Stock Crash
12:58pm, Tuesday, 25'th Nov 2025
Novo Nordisk (NVO) may be trying to script a new chapter in a year that has tested every inch of investor patience. Fresh data released Tuesday suggest its next
Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention
12:39pm, Tuesday, 25'th Nov 2025
Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
12:10pm, Tuesday, 25'th Nov 2025
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients
10:08am, Tuesday, 25'th Nov 2025
Novo Nordisk A/S (NYSE: NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.
Final Trade: BABA, ZM, NVO, TJX
09:56am, Tuesday, 25'th Nov 2025
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
What's Happening With Novo Nordisk Stock?
09:50am, Tuesday, 25'th Nov 2025
Novo Nordisk's stock has faced pressure following its Ozempic pill's failure in Alzheimer's disease trials, introducing new downside risks for the leader in weight loss medications. While Eli Lilly st
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.
09:08am, Tuesday, 25'th Nov 2025
Novo Nordisk stock was rebounding in premarket trading Tuesday. It's a tale of two drug trials.
